Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.400
-0.120 (-2.65%)
May 18, 2026, 4:00 PM EDT - Market closed
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $2.00M in the quarter ending March 31, 2026, with 37.18% growth. This brings the company's revenue in the last twelve months to $8.37M, down -52.94% year-over-year. In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%.
Revenue (ttm)
$8.37M
Revenue Growth
-52.94%
P/S Ratio
73.45
Revenue / Employee
$114,616
Employees
73
Market Cap
614.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| Zevra Therapeutics | 122.29M |
| Gyre Therapeutics | 117.05M |
| Sutro Biopharma | 99.61M |
| Arvinas | 89.40M |
| Crescent Biopharma | 11.88M |
ACRS News
- 4 days ago - Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Aclaris Therapeutics Slides: FY 2026 - Filings
- 10 days ago - Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - GlobeNewsWire
- 11 days ago - Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c) - TheFly
- 11 days ago - Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c) - TheFly
- 12 days ago - Aclaris Therapeutics Earnings release: Q1 2026 - Filings
- 12 days ago - Aclaris Therapeutics Quarterly report: Q1 2026 - Filings
- 12 days ago - Aclaris Therapeutics Slides: Corporate presentation - Filings